370 related articles for article (PubMed ID: 34644431)
1. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
Janbain M; Enjolras N; Bordet JC; Bolbos R; Brevet M; Leissinger C; Dargaud Y
J Thromb Haemost; 2020 Mar; 18(3):584-592. PubMed ID: 31782901
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.
Yada K; Nogami K; Shinozawa K; Kitazawa T; Hattori K; Amano K; Fukutake K; Shima M
Br J Haematol; 2018 Oct; 183(2):257-266. PubMed ID: 30125997
[TBL] [Abstract][Full Text] [Related]
5. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
6. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
[TBL] [Abstract][Full Text] [Related]
7. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
[TBL] [Abstract][Full Text] [Related]
8. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
[TBL] [Abstract][Full Text] [Related]
11. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
[TBL] [Abstract][Full Text] [Related]
12. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
[TBL] [Abstract][Full Text] [Related]
13. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
Ebbert PT; Xavier F; Seaman CD; Ragni MV
Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
[TBL] [Abstract][Full Text] [Related]
15. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
[TBL] [Abstract][Full Text] [Related]
16. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
17. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
18. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
[TBL] [Abstract][Full Text] [Related]
19. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
[TBL] [Abstract][Full Text] [Related]
20. Emicizumab: A Review in Haemophilia A.
Blair HA
Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
